top of page

CCOA Therapeutics Has Launched a COVID-19

Response Program

Toronto, March 16, 2020

WeChat Image_20200408130821.jpg

CCOA Biotechnology at CCOA Therapeutics has launched a new program for the prevention and treatment of COVID-19, including development and production of preventative agents against COVID-19; production of recombinant SARS-CoV-2 spike glycoprotein and recombinant angiotensin-converting enzyme 2 protein; developing novel anti-SARS-CoV-2 drugs including monoclonal antibody and aptamer drugs; establishing a new anti-SARS-CoV-2 antibody detection kit; design and manufacture novel medical devices to purify neutralizing antibodies from COVID-19 patients in the recovery phase. 

Visit

4th floor, 209 Victoria Street, Toronto, ON, Canada M5B 1T8

Call

T: 1-4168646060 (#77610)

F: 1-4168471738

截屏2020-02-03下午4.47.31.png
  • facebook
  • Twitter Clean
bottom of page